Pegdinetanib Withdrawn Phase 1 Trials for Neoplasms Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01146171Japanese Phase 1 Study of BMS-844203 (CT322)